Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 2,552 shares of Natera stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total value of $233,201.76. Following the completion of the transaction, the chief executive officer now owns 230,319 shares of the company’s stock, valued at approximately $21,046,550.22. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Steven Leonard Chapman also recently made the following trade(s):
- On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The stock was sold at an average price of $93.13, for a total transaction of $634,774.08.
- On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $240,698.04.
- On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total transaction of $7,403,518.08.
- On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $824,045.36.
- On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The stock was sold at an average price of $65.09, for a total value of $964,178.17.
Natera Price Performance
Shares of NASDAQ NTRA opened at $91.50 on Thursday. The business has a 50-day simple moving average of $86.85 and a two-hundred day simple moving average of $66.82. The company has a market cap of $11.05 billion, a PE ratio of -24.29 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82.
Institutional Trading of Natera
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. RiverPark Advisors LLC purchased a new stake in Natera in the fourth quarter valued at $27,000. Principal Securities Inc. acquired a new position in shares of Natera in the 4th quarter valued at about $32,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Natera in the third quarter worth about $44,000. Oliver Lagore Vanvalin Investment Group grew its holdings in Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares during the period. Finally, Arcadia Investment Management Corp MI raised its position in Natera by 47.8% during the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 174 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on NTRA. Canaccord Genuity Group boosted their price objective on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Tuesday. BTIG Research increased their price objective on shares of Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and increased their target price for the company from $68.00 to $85.00 in a research report on Tuesday, February 20th. Finally, Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a research report on Friday, April 5th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.
View Our Latest Stock Report on Natera
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Read More
- Five stocks we like better than Natera
- The How And Why of Investing in Oil Stocks
- High-Yield Texas Instruments Could Hit New Highs Soon
- What Are Dividend Contenders? Investing in Dividend Contenders
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Comparing and Trading High PE Ratio Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.